Arpit Rao, MD, discusses the rationale and importance of the phase 3 CASPAR trial in castration-resistant prostate cancer.
Arpit Rao, MD, associate professor, medical oncology, Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the rationale and importance of the phase 3 CASPAR trial (NCT04455750) in castration-resistant prostate cancer (mCRPC).
The randomized, phase 3 trial is examining the combination of rucaparib (Rubraca) and enzalutamide (Xtandi) therapy vs enzalutamide monotherapy in the first line for patients mCRPC, Rao explains. The addition of androgen-receptor inhibition with PARP therapy, induces synthetic lethality, a state where cells become acutely sensitive to any damage to their DNA, such as cellular death, Rao says.
Moreover, findings from a recent phase 2 trial, which examined abiraterone acetate (Zytiga) and olaparib (Lynparza), produced a signal of efficacy for the first time in this patient population, leading to the inception of the CASPAR trial, Rao concludes.